- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 31, 2020
Distillery Therapeutics
T cell-specific targeting of KCNA3 for lupus nephritis
DISEASE CATEGORY: Autoimmune disease
INDICATION: Lupus Lipid nanoparticle-based T-cell specific inhibition of the potassium channel KCNA3 could treat lupus nephritis. The nanoparticles contain an
INDICATION: Lupus Lipid nanoparticle-based T-cell specific inhibition of the potassium channel KCNA3 could treat lupus nephritis. The nanoparticles contain an
BioCentury | May 11, 2015
Product Development
Check your effectors
Phase Ib data suggest Kineta's Kv1.3 blocker may quell autoimmune flares
Items per page:
1 - 3 of 3